UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended: June 30, 2015
[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _________ to __________

[X]	QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: SEPTEMBER 30, 2015

[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to __________

Commission file number: 333-198110

SIGNPATH PHARMA INC.

(Exact name of Registrant as specified in its charter)

Delaware		20-5079533
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

3477 Corporate Parkway, Suite 100 ~~Center Valley, PA 18034 (Address of principal executive offices)~~

~~(215)~~Center ~~538-9996 (Registrant’s telephone number~~Valley, ~~including~~PA ~~Area Code)~~18034

(Address of principal executive offices)

(215) 538-9996

(Registrant’s telephone number, including Area Code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X ] Yes [ X] No

The reporter filed the report voluntarily.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated file” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]

Non-accelerated filer [ ]	Smaller reporting company [X]

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

APPLICABLE ONLY TO CORPORATE ISSUERS

As of ~~August~~November 13, 2015, the Company had 14,163,887 shares of the Registrant’s common stock, par value $0.001 per share, issued and outstanding.

SignPath Pharma Inc. Quarterly Report on Form 10-Q Period Ended September 30, 2015

Quarterly Report on Form 10-Q

Period Ended June 30, 2015

TABLE OF CONTENTS

	Page
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements: (unaudited)
Item1. Financial Statements: (unaudited)	3
Condensed Balance Sheets as of June 30, 2015 and December 31, 2014	3
Condensed Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014 (audited)	3
Condensed Statements of Operations for the three and six months ended June 30, 2015 and 2014	4
Condensed Statements of Operations for the three and nine months ended September 30, 2015 and 2014	4
Condensed Statements of Cash Flows for the six months ended June, 2015 and 2014	5
Condensed Statements of Cash Flows for the nine months ended September 30, 2015 and 2014	5
Notes to Condensed Financial Statements	6~~-10~~
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations & Plan of Operations	~~11-13~~12
Item 3. Quantitative and Qualitative Disclosures About Market Risk	1314
Item 4. Controls and Procedures	14
PART II. OTHER INFORMATION
Item 1.1. Legal Proceedings	1415
Item 1.1A. Risk Factors – Not Applicable	1415
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	1415
Item 3. Defaults Upon Senior Securities	1415
Item 4. Mine Safety Disclosures	1415
Item 5. Other Information	1415
Item 6. Exhibits	1516
SIGNATURES	1617
Exhibits	1718

~~PART I. FINANCIAL INFORMATION~~2

~~Item~~SIGNPATH PHARMA, 1INC. ~~Financial Statements~~

~~SIGNPATH~~Condensed ~~PHARMA,~~Balance ~~INC.~~Sheets

~~Condensed Balance Sheets~~(unaudited)

(unaudited)

	September 30, 2015			December 31, 2014

ASSETS

CURRENT ASSETS

Cash	$	498,101		$	716,193
Prepaid expenses		7,152			-

Total Current Assets		505,253			716,193

TOTAL ASSETS	$	505,253		$	716,193

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES

Accounts payable and accrued expenses	$	303,462		$	447,999

Total Current Liabilities		303,462			447,999

STOCKHOLDERS’ EQUITY

Convertible Preferred Stock, 5,000,000 shares authorized, $0.10 par value
Series A; 5,000 shares authorized 3,256 shares issued and outstanding, respectively		326			326
Series B; 3,000 shares authorized 2,146 shares issued and outstanding, respectively		215			215
Series C; 6,000 shares authorized 5,001 and 5,001 shares issued and outstanding, respectively		500			500
Series D; 6,000 shares authorized 1,589 and 320 shares issued and outstanding, respectively		160			32
Common stock; $0.001 par value, 50,000,000 shares authorized; 14,163,887 and 14,123,887 shares issued and outstanding, respectively		14,164			14,124
Accrued dividends		1,530,429			969,230
Additional paid-in capital		13,435,837			12,700,365
Accumulated deficit		(14,779,840	)		(13,416,598	)

Total Stockholders’ Equity		201,791			268,194

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	505,253		$	716,193

	June 30, 2015			December 31, 2014
ASSETS
CURRENT ASSETS
Cash	$	665,781		$	716,193
Total Current Assets		665,781			716,193
TOTAL ASSETS	$	665,781		$	716,193
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	327,789		$	447,999
Total Current Liabilities		327,789			447,999
STOCKHOLDERS’ EQUITY (DEFICIT)
Convertible Preferred Stock, 5,000,000 shares authorized, $0.10 par value
Series A; 5,000 shares authorized 3,256 shares issued and outstanding, respectively		326			326
Series B; 3,000 shares authorized 2,146 shares issued and outstanding, respectively		215			215
Series C; 6,000 shares authorized 5,001 and 5,001 shares issued and outstanding, respectively		500			500
Series D; 6,000 shares authorized 1,265 and 320 shares issued and outstanding, respectively		127			32
Common stock; $0.001 par value, 50,000,000 shares authorized; 14,163,887 and 14,123,887 shares issued and outstanding, respectively		14,164			14,124
Accrued dividends		1,335,639			969,230
Additional paid-in capital		13,289,765			12,700,365
Accumulated deficit		(14,302,744	)		(13,416,598	)
Total Stockholders’ Equity		337,992			268,194
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	665,781		$	716,193

The accompanying notes are an integral part of these financial statements.

~~The accompanying notes are an integral part of these financial statements.~~3

3SIGNPATH PHARMA, INC.

~~SIGNPATH~~Condensed ~~PHARMA,~~Statements ~~INC.~~of Operations

~~Condensed Statements of Operations~~(unaudited)

(unaudited)

	For the Three Months Ended,						For the Nine Months Ended,
	September 30,						September 30,
	2015			2014			2015			2014
REVENUES
	$	-		$	-		$	-		$	-

OPERATING EXPENSES

General and administrative		36,914			45,852			157,181			60,041
Professional fees		45,811			88,204			266,472			320,176
Research and development		274,157			799,965			683,802			1,546,500
Salaries and wages		118,794			45,207			268,063			209,527

Total Operating Expenses		(475,676	)		(978,958	)		(1,375,518	)		(2,136,244	)

OPERATING LOSS		(475,676	)		(978,958	)		(1,375,518	)		(2,136,244	)

OTHER INCOME (EXPENSE)

Other Income		-			-			23,641			-
Foreign currency loss		(1,436	)		(4,003	)		(11,420	)		(4,003	)
Interest income		16			171			55			568

Total Other Income (Expense)		(1,420	)		(3,832	)		12,276			(3,435	)

NET LOSS BEFORE INCOME TAXES		(477,096	)		(982,790	)		(1,363,242	)		(2,139,679	)
Provision for income taxes		-			-			-			-

NET LOSS	$	(477,096	)	$	(980,790	)	$	(1,363,242	)	$	(2,139,679	)

PREFERRED STOCK DIVIDEND		(194,794	)		(141,427	)	$	(561,199	)		(467,624	)

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(671,890	)	$	(1,124,217	)	$	(1,924,441	)	$	(2,607,303	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.05	)	$	(0.09	)	$	(0.14	)	$	(0.20	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING		14,163,887			12,877,500			14,163,887			12,877,500

	For the Three Months Ended,						For the Six Months Ended,
	June 30,						June 30,
	2015			2014			2015			2014
REVENUES
	$	-		$	-		$	-		$	-
OPERATING EXPENSES
General and administrative		69,728			6,700			120,267			14,460
Professional fees		103,495			227,719			220,661			231,970
Research and development		193,141			616,750			409,645			746,538
Salaries and wages		81,382			107,745			149,269			164,318
Total Operating Expenses		(447,746	)		(958,913	)		(899,842	)		(1,157,285	)
OPERATING LOSS		(447,746	)		(958,913	)		(899,842	)		(1,157,285	)
OTHER INCOME (EXPENSE)
Other Income		5,240			-			23,641			-
Foreign currency loss		1,802			-			(9,984	)		-
Interest income		22			200			39			397
Total Other Income (Expense)		7,064			200			13,696			397
NET LOSS BEFORE INCOME TAXES		(440,682	)		(958,713	)		(886,146	)		(1,156,889	)
Provision for income taxes		-			-			-			-
NET LOSS	$	(440,682	)	$	(958,713	)	$	(886,146	)	$	(1,156,889	)
PREFERRED STOCK DIVIDEND		(189,078	)		(958,713	)		(366,409	)		(155,769	)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(629,760	)	$	(958,713	)	$	(1,252,555	)	$	(1,156,889	)
BASIC AND DILUTED LOSS PER SHARE	$	(0.04	)	$	(0.07	)	$	(0.09	)	$	(0.09	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING		14,163,887			12,877,500			14,163,887			12,877,500

The accompanying notes are an integral part of these financial statements.

~~The accompanying notes are an integral part of these financial statements.~~4

4Condensed Statements of Cash Flows

~~SIGNPATH~~Condensed ~~PHARMA,~~Statements ~~INC.~~of Cash Flows

~~Condensed Statements of Cash Flows~~(unaudited)

(unaudited)

	For the Nine Months Ended,
	September 30,
	2015			2014
OPERATING ACTIVITIES
Net loss	$	(1,363,242	)	$	(2,139,679	)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services		-			51,000
Stock options compensation		143,488			186,384
Stock issued for compensation		16,000			-
Loss on equity modification		29,610			13,132
Changes in operating assets and liabilities
Change in prepaid expenses		(7,152	)		-
Accounts payable and accrued expenses		(110,535	)		452,999
Net Cash Used in Operating Activities		(1,291,831	)		(1,436,164	)

FINANCING ACTIVITIES
Preferred stock issued for cash, net of stock offering costs		1,073,739			1,372,536
Net Cash Provided by Financing Activities		1,073,739			1,372,536

NET INCREASE (DECREASE) IN CASH		(218,092	)		(63,628	)
CASH AT BEGINNING OF PERIOD		716,193			1,241,397

CASH AT END OF PERIOD	$	498,101		$	1,177,769

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

NON CASH FINANCING ACTIVITIES:
Common stock issued for dividends	$	-		$	1,025,404
Issuance of shares for accrued fees	$	34,000		$	-
Preferred dividend accrual	$	561,199		$	467,624

	For the Six Months Ended,
	June 30,
	2015			2014
OPERATING ACTIVITIES
Net loss	$	(886,146	)	$	(1,156,889	)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services		-			51,000
Stock options compensation		75,538			173,386
Stock issued for compensation		16,000			-
Loss on equity modification		29,610			-
Changes in operating assets and liabilities
Accounts payable and accrued expenses		(86,209	)		(40,857	)
Net Cash Used in Operating Activities		(851,207	)		(973,360	)
FINANCING ACTIVITIES
Preferred stock issued for cash, net of stock offering costs		800,795			1,372,536
Net Cash Provided by Financing Activities		800,795			1,372,536
NET INCREASE (DECREASE) IN CASH		(50,412	)		399,176
CASH AT BEGINNING OF PERIOD		716,193			1,241,397
CASH AT END OF PERIOD	$	665,781		$	1,640,573
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
NON CASH FINANCING ACTIVITIES:
Issuance of shares for accrued fees	$	34,000		$	-
Preferred dividend accrual	$	366,409		$	155,769

The accompanying notes are an integral part of these financial statements.

~~The accompanying notes are an integral part of these financial statements.~~5

5NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

~~SIGNPATH~~Basis ~~PHARMA,~~of ~~INC. Notes to Condensed Financial Statements (unaudited)~~Presentation

~~NOTE~~These 1financial –statements ~~DESCRIPTION~~and OFrelated ~~BUSINESS~~notes ~~AND~~are ~~BASIS~~presented OFin ~~PRESENTATION~~accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31.

~~Basis~~The accompanying unaudited condensed financial statements have been prepared by the Company without audit. In the opinion of ~~Presentation~~management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2015, and for all periods presented herein, have been made.

~~These~~Certain ~~financial~~information ~~statements~~ and ~~related~~footnote ~~notes~~disclosures ~~are~~normally ~~presented~~included in financial statements prepared in accordance with accounting principles generally accepted in the United States, ~~and~~of ~~are~~America ~~expressed~~have inbeen ~~U.S.~~condensed ~~dollars~~or omitted. ~~The~~It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s ~~fiscal~~December ~~year-end~~31, 2014 isaudited ~~December~~financial 31statements filed with the SEC on April 9, 2015. The results of operations for the period ended September 30, 2015 are not necessarily indicative of the operating results for the full year.

~~The~~Description ~~accompanying unaudited condensed financial statements have been prepared by the Company without audit. In the opinion~~ of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2015, and for all periods presented herein, have been made.Business

~~Certain~~Throughout ~~information~~this ~~and~~report, ~~footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in~~ the ~~United~~terms ~~States~~“we,” of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31“us, ~~2014~~” ~~audited financial statements filed with the SEC on April 9~~“our,” ~~2015. The results of operations for the period ended June 30~~“registrant,” “Company” ~~2015~~refer ~~are~~to ~~not~~SignPath ~~necessarily~~Pharma ~~indicative of the operating results for the full year~~Inc.

~~Description of~~ Business

~~Throughout~~SignPath ~~this~~is ~~report~~a clinical stage biotechnology company founded in May 2006 to develop synthesized proprietary formulations of curcumin, a naturally occurring compound found in the ~~terms~~root ~~“we,”~~of ~~“us,”~~the ~~“our,”~~Curcuma ~~“registrant~~longa Linn (turmeric) plant,” ~~“Company”~~for applications in human diseases Good Manufacturing ~~refer~~Practice to(GMP) ~~SignPath~~synthesis ~~Pharma~~renders ~~Inc~~the curcumin active pharmaceutical ingredient (API) 99.2% pure. The Company is a publicly held non-traded Delaware corporation.

~~Business~~During the nine months ended September 30, 2015 and 2014, the Company expended $683,802 and $1,546,500 respectively, for net research and development. None of these expenses were borne by customers as the final products are not commercially available. They consisted primarily of payments made to commercial and academic institutions.

~~SignPath~~NOTE is a clinical stage biotechnology company founded in May 2006 to develop synthesized proprietary formulations of curcumin, a naturally occurring compound found in the root of the Curcuma longa Linn (turmeric) plant, for applications in human diseases Good Manufacturing Practice (GMP) synthesis renders the curcumin active pharmaceutical ingredient (API) 99.2% ~~pure.~~– ~~The~~GOING ~~Company is a publicly held non-traded Delaware corporation.~~CONCERN

~~During~~The Company’s financial statements are prepared using generally accepted accounting principles in the ~~six~~United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. During the nine months ended ~~June~~September 30, 2015 ~~and 2014~~, the Company ~~expended~~recognized sales revenue of $~~409~~-0- and incurred a net loss of $1,~~645~~363,242. ~~and~~As of September 30, 2015, the Company had an accumulated deficit of $~~746~~14,~~538~~779,840. ~~respectively~~The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, ~~for~~the ~~net~~ability ~~research~~to raise equity or debt financing, and ~~development. None~~the attainment of ~~these~~profitable ~~expenses~~operations ~~were~~from ~~borne~~the byCompany’s ~~customers~~planned asbusiness. If the ~~final~~Company is ~~products~~unable ~~are~~to ~~not~~obtain ~~commercially~~adequate ~~available~~capital, it could be forced to cease operations. ~~They~~These ~~consisted~~consolidated ~~primarily~~financial statements do not include any adjustments to the recoverability and classification of ~~payments~~recorded ~~made~~asset amounts and classification of liabilities that might be necessary should the Company be unable to ~~commercial~~continue ~~and~~as ~~academic~~a ~~institutions~~going concern.

~~NOTE~~In 2order ~~– GOING~~to ~~CONCERN~~continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plan is to obtain such resources for the Company by obtaining capital from significant shareholders sufficient to meet its operating expenses and seeking equity and/or debt financing from third parties. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The ~~Company’s~~ability ~~financial statements are prepared using generally accepted accounting principles in the United States~~ of ~~America applicable to a going concern which contemplates~~ the ~~realization of assets and liquidation of liabilities in the normal course of business. The~~ Company ~~has not yet established an ongoing source of revenues sufficient~~ to ~~cover its operating costs and allow it to~~ continue as a going concern. ~~During~~is ~~the~~dependent ~~six~~upon ~~months~~its ~~ended~~ability ~~June~~to ~~30,~~successfully ~~2015,~~accomplish the ~~Company~~plans ~~recognized sales revenue of $-0- and~~described ~~incurred~~in ~~a net loss of $886,146. As of June 30, 2015,~~ the ~~Company~~preceding ~~had~~paragraph anand ~~accumulated~~eventually ~~deficit~~secure ofother ~~$14,302,744.~~sources ~~The continuation~~ of ~~the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability to raise equity or debt~~ financing, and ~~the~~attain ~~attainment of~~ profitable operations ~~from the Company’s planned business~~. IfThe ~~the~~accompanying ~~Company is unable to obtain adequate capital, it could be forced to cease operations. These consolidated~~ financial statements do not include any adjustments ~~to the recoverability and classification of recorded asset amounts and classification of liabilities~~ that might be necessary ~~should~~if the Company beis unable to continue as a going concern.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plan is to obtain such resources for the Company by obtaining capital from significant shareholders sufficient to meet its operating expenses and seeking equity and/or debt financing from third parties. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.6

~~The~~NOTE ~~ability~~3 of– ~~the~~SUMMARY ~~Company~~OF toSIGNIFICANT ~~continue~~ACCOUNTING as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.POLICIES

6Use of Estimates

~~NOTE~~The 3preparation –of ~~SUMMARY~~financial OFstatements ~~SIGNIFICANT~~in ~~ACCOUNTING~~conformity ~~POLICIES~~with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

~~Use~~Cash ofand ~~Estimates~~Cash Equivalents

The ~~preparation~~Company ofconsiders ~~financial~~all ~~statements~~highly inliquid ~~conformity~~instruments with ~~accounting~~maturity ~~principles generally accepted in the United States~~ of ~~America requires~~three ~~management~~months toor ~~make~~less ~~estimates~~at ~~and assumptions that affect~~ the ~~reported~~time ~~amounts~~ of ~~assets~~issuance ~~and~~to ~~liabilities~~be atcash ~~the date of~~equivalents. ~~the~~There ~~financial~~were ~~statements~~no ~~and~~cash ~~the~~equivalents ~~reported~~as ~~amounts~~ of ~~revenue~~September ~~and~~30, ~~expenses~~2015 ~~during~~or ~~the~~December ~~reporting~~31, ~~period~~2014. ~~Actual results could differ from those estimates.~~

~~Accounting~~Concentration ~~Basis~~of Credit Risk

~~The~~Financial ~~Company’s~~instruments, ~~financial~~which ~~statements~~potentially ~~are~~subject ~~prepared~~us ~~using~~to ~~the~~concentrations ~~accrual~~of ~~basis~~credit ofrisk, ~~accounting~~consist inprincipally ~~accordance~~of ~~with~~cash. ~~accounting~~Our ~~principles generally~~cash ~~accepted~~balances are maintained in ~~the~~accounts ~~United~~held ~~States.~~by ~~The~~major ~~Company~~banks ~~has~~and ~~elected~~financial ainstitutions ~~December~~located 31in ~~fiscal~~the ~~year~~United ~~end~~States.

~~Cash~~The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had $248,101 and ~~Cash~~$466,193 ~~Equivalents~~of cash balances in excess of federally insured limits at September 30, 2015 and December 31, 2014, respectively.

~~The~~Fair ~~Company~~Value ~~considers all highly liquid instruments with maturity~~ of ~~three~~Financial ~~months~~Instruments ~~or less at the time of issuance to be cash equivalents. There were no cash equivalents as of June 30, 2015 or December 31, 2014.~~

~~Concentration~~In accordance with ASC 820, the carrying value of ~~Credit~~cash ~~Risk~~and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

~~Financial~~Level ~~instruments,~~1-Inputs ~~which~~are ~~potentially~~unadjusted ~~subject~~quoted usprices ~~to concentrations of credit risk, consist principally of cash. Our cash balances are maintained~~ in ~~accounts~~active ~~held~~markets byfor ~~major~~identical ~~banks~~assets ~~and~~or ~~financial~~liabilities ~~institutions~~available ~~located~~at in the ~~United~~measurement ~~States~~date.

~~The~~Level ~~Company~~2-Inputs ~~occasionally~~are ~~maintains~~unadjusted ~~amounts~~quoted onprices ~~deposit~~for ~~with~~similar aassets ~~financial~~and ~~institution~~liabilities ~~that are~~ in ~~excess~~active ~~of the federally insured limit of $250~~markets,~~000.~~ ~~The~~quoted ~~risk~~prices isfor ~~managed~~identical byor ~~maintaining~~similar assets ~~all~~and ~~deposits~~liabilities in ~~high~~markets ~~quality~~that ~~financial~~are ~~institutions.~~not ~~The Company had $415~~active,~~781 and~~ ~~$466,193~~inputs ofother ~~cash~~than ~~balances~~quoted inprices ~~excess~~that ofare ~~federally~~observable, ~~insured~~and ~~limits~~inputs atderived from ~~June~~or ~~30,~~corroborated ~~2015~~by ~~and~~observable ~~December~~market ~~31, 2014, respectively~~data.

~~Fair~~Level ~~Value~~3-Inputs ofare ~~Financial~~unobservable ~~Instruments~~inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

InThe ~~accordance~~carrying ~~with~~amounts ~~ASC~~reported ~~820,~~in the ~~carrying~~balance ~~value~~sheets offor cash ~~and cash equivalents~~, accounts ~~receivable~~payable and ~~accounts~~accrued ~~payable~~expenses ~~approximates~~ approximate their fair market value ~~due~~based toon the short-term maturity of these instruments. ~~ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:~~

~~Level~~Research ~~1-Inputs~~and ~~are~~Development ~~unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.~~Costs

~~Level~~The ~~2-Inputs~~Company ~~are~~expenses ~~unadjusted~~the ~~quoted~~costs ~~prices~~of ~~for~~the ~~similar~~development ~~assets~~of ~~and~~its ~~liabilities~~pharmaceutical inproducts ~~active~~during ~~markets,~~the ~~quoted~~period ~~prices~~incurred. ~~for~~The ~~identical~~Company ~~or similar~~incurred ~~assets~~research and ~~liabilities~~development inexpenses ~~markets~~of ~~that~~$683,802 ~~are~~and ~~not active~~$1,546,500 ~~inputs~~during ~~other~~the ~~than~~nine ~~quoted~~months ~~prices~~ended ~~that~~September ~~are observable~~30, 2015 and ~~inputs~~2014, ~~derived from or corroborated by observable market data~~respectively.

~~Level 3~~Stock-~~Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants~~Based ~~would use in pricing the asset or liability based on the best available information.~~Compensation

The ~~carrying~~Company ~~amounts~~follows ~~reported~~the inprovisions ~~the~~of ~~balance~~ASC ~~sheets~~718 ~~for~~which ~~cash,~~requires ~~accounts~~all ~~payable~~share-based ~~and~~payments ~~accrued~~to ~~expenses~~employees, ~~approximate~~including ~~their~~grants ~~fair~~of ~~market~~employee stock ~~value~~options, to be recognized in the income statement based on their fair values. The Company uses the ~~short~~Black-~~term~~Scholes ~~maturity~~pricing model for determining the fair value of ~~these~~stock ~~instruments~~based compensation.

~~Research~~Equity instruments issued to non-employees for goods or services are accounted for at fair value and ~~Development~~are ~~Costs~~marked to market until service is complete or a performance commitment date is reached, whichever is earlier.

The Company expenses the costs of the development of its pharmaceutical products during the period incurred. The Company incurred research and development expenses of $409,645 and $746,538 during the six months ended June 30, 2015 and 2014, respectively.7

~~Stock-Based~~Related ~~Compensation~~Party Transactions

~~The~~For ~~Company follows~~ the ~~provisions~~period ofended ~~ASC~~September ~~718~~30, ~~which~~2015 ~~requires~~the ~~all~~Company ~~share-based~~had ~~payments~~an toemployee ~~employees,~~payable ~~including~~in ~~grants~~the amount of ~~employee stock options~~$5,554 related to bereimbursable ~~recognized~~company expenses indue ~~the~~to ~~income~~Kai ~~statement~~Larson, ~~based~~Vice onPresident ~~their~~of ~~fair~~Corporate ~~values.~~Development, ~~The~~Chief ~~Company~~Operating ~~uses~~Officer, ~~the~~and ~~Black-Scholes~~Secretary ~~pricing~~to ~~model for determining~~ the ~~fair value of stock based compensation~~Company.

~~Equity~~For ~~instruments~~the ~~issued~~period toended ~~non-employees~~September ~~for~~30, ~~goods~~2015 orthe ~~services~~Company ~~are~~had ~~accounted~~a ~~for~~payable atdue ~~fair~~to ~~value~~Dr. ~~and~~Larry ~~are~~Helson ~~marked~~related to ~~market~~Medicare ~~until~~coverage ~~service~~for the time ishe ~~complete~~has orbeen aemployed ~~performance~~by ~~commitment~~the ~~date~~Company. The total amount due is ~~reached~~$30,000 ~~whichever~~to isbe ~~earlier~~paid out at a rate of $2,900 per annum.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

7In July, 2006, the FASB issued ASC 740, Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification and disclosure of tax positions, along with accounting for the related interest and penalties. ASC 740 became effective as of January 1, 2007 and had no impact on the Company’s financial statements.

InThe ~~July,~~charge ~~2006,~~for ~~the~~taxation ~~FASB~~is ~~issued~~based ~~ASC~~on ~~740,~~the ~~Accounting~~results for ~~Uncertainty~~the inyear ~~Income~~as ~~Taxes,~~adjusted ~~which clarifies the accounting~~ for ~~uncertainty in~~items, ~~tax~~which ~~positions~~are ~~taken~~non-assessable or ~~expected to be taken in a return~~disallowed. ~~ASC~~It ~~740 provides guidance on the measurement, recognition, classification~~is ~~and~~calculated ~~disclosure~~using of tax ~~positions,~~rates ~~along~~that ~~with~~have ~~accounting~~been ~~for~~enacted ~~the~~or ~~related~~substantively ~~interest~~enacted ~~and~~by ~~penalties. ASC 740 became effective as of January 1, 2007 and had no impact on~~ the ~~Company’s~~balance ~~financial~~sheet ~~statements~~date.

~~The~~Basic ~~charge~~and ~~for~~Diluted ~~taxation~~Net isincome ~~based~~(Loss) onper ~~the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.~~Share

~~Basic~~The ~~and~~Company ~~Diluted~~computes ~~Net~~net income (~~Loss~~loss) per ~~Share~~share in accordance with ASC 260 which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

~~The~~For ~~Company~~the ~~computes~~nine ~~net~~months ~~income~~ended ~~(loss)~~September ~~per~~30, ~~share~~2015 ~~in accordance with ASC 260 which requires presentation of both basic~~ and ~~diluted earnings~~2014, ~~per~~all ~~share (EPS) on the face~~ of the ~~income~~Company’s ~~statement.~~potentially ~~Basic~~dilutive ~~EPS~~securities ~~is computed by dividing net income~~ (~~loss)~~warrants, ~~available to~~options, ~~common~~convertible ~~shareholders~~preferred ~~(numerator~~stock) bywere ~~the~~excluded ~~weighted~~from ~~average~~the ~~number~~computation of ~~shares~~diluted ~~outstanding~~earnings ~~(denominator)~~per ~~during~~share ~~the~~as ~~period.~~they ~~Diluted EPS~~were ~~gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if~~anti-~~converted method~~dilutive. ~~In computing Diluted EPS, the average stock price for the period is used in determining~~The ~~the~~total number of ~~shares~~potentially ~~assumed~~dilutive toCommon beShares ~~purchased~~that ~~from~~were ~~the~~excluded ~~exercise~~were of25,685,789 ~~stock~~and ~~options~~20,675,814 orat ~~warrants.~~September ~~Diluted~~30, ~~EPS~~2015 ~~excludes all dilutive~~and ~~potential~~2014, ~~shares if their effect is anti-dilutive~~respectively.

~~For~~NOTE ~~the~~4 ~~six~~– ~~months~~ACCRUED ended June 30, 2015 and 2014, all of the Company’s potentially dilutive securities (warrants, options, convertible preferred stock) were excluded from the computation of diluted earnings per share as they were anti-dilutive. The total number of potentially dilutive Common Shares that were excluded were 25,442,831, and 20,675,814 at June 30, 2015 and 2014, respectively.LIABILITIES

~~NOTE~~The 4Company –has ~~ACCRUED~~concluded ~~LIABILITIES~~it is probable that it will pay $85,738 in liquidated damages pursuant to the registration rights clause in certain of the securities sold in fiscal years 2008 and 2009, the Company was required to file a registration statement by January 27, 2009. The Company failed to do so until April 7, 2009, resulting in liquidated damages of 2% per month of the gross proceeds, which approximated $1.8 million as of that date. During the year ended December 31, 2009, the Company’s registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned.

~~The~~NOTE ~~Company~~5 ~~has~~– ~~concluded~~PREFERRED it is probable that it will pay $85,738 in liquidated damages pursuant to the registration rights clause in certain of the securities sold in fiscal years 2008 and 2009, the Company was required to file a registration statement by January 27, 2009. The Company failed to do so until April 7, 2009, resulting in liquidated damages of 2% per month of the gross proceeds, which approximated $1.8 million as of that date. During the year ended December 31, 2009, the Company’s registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share ownedSTOCK

~~NOTE~~The Company has authorized 5,000,000 –shares ~~PREFERRED~~of ~~STOCK~~Preferred Stock, $.10 par value, of which, as of September 30, 2015, an aggregate of 11,992 shares were issued and outstanding consisting of (i) 5,000 shares of Series A Convertible Preferred Stock authorized and 3,256 shares issued and outstanding, (ii) 3,000 shares of Series B Convertible Preferred Stock authorized and 2,146 shares were issued and outstanding, (iii) 6,000 shares of Series C Convertible Preferred Stock authorized and 5,001 shares were issued and outstanding, and (iv) 6,000 shares of Series D Convertible Preferred Stock are authorized, 1,589 of which were issued and outstanding.

The Company has authorized 5,000,000 shares of Preferred Stock, $.10 par value, of which, as of June 30, 2015, an aggregate of 11,668 shares were issued and outstanding consisting of (i) 5,000 shares of Series A Convertible Preferred Stock authorized and 3,256 shares issued and outstanding, (ii) 3,000 shares of Series B Convertible Preferred Stock authorized and 2,146 shares were issued and outstanding, (iii) 6,000 shares of Series C Convertible Preferred Stock authorized and 5,001 shares were issued and outstanding, and (iv) 6,000 shares of Series D Convertible Preferred Stock are authorized, 1,265 of which were issued and outstanding.8

For the ~~six~~nine months that ended ~~June~~September 30, 2015 the Company issued ~~945~~1,269 shares of Series D Preferred Stock. Gross proceeds received ~~for~~ for these shares was $~~945~~1,~~249~~269,076 offset by stock offering costs of $~~144~~195,~~454~~337 issued to the placement agent, a related party.

NOTE 6 – COMMON STOCK

On January 1, 2015, the Company granted 40,000 shares of common stock to Jack Levine, Audit Committee Chair, for services rendered during 2014. These shares were issued at a fair value of $1.25 per share. The stock payable amount recorded year ended December 31, 2014 was valued at a stock price of $0.85. The excess of the fair value of the shares over the amount accrued at December 31, 2014 was recognized as compensation expense during the quarter ended ~~June~~September 30, 2015. For the ~~six~~nine months ended ~~June~~ September 30, 2015, $16,000 was recognized as salaries and wages.

8NOTE 7 – WARRANTS AND OPTIONS

~~NOTE 7 – WARRANTS AND OPTIONS~~Warrants

~~Warrants~~A summary of the status of the Company’s warrants as of September 30, 2015 and December 31, 2014 are presented below:

A summary of the status of the Company’s warrants as of June 30, 2015 and December 31, 2014 are presented below:

	Number of Warrants			Weighted Average Exercise Price			Remaining Term (years)

Outstanding as of December 31, 2014		12,550,062			1.25			4.60
Granted		2,939,123			1.36			5.63
Cancelled		(2,621,851	)		(1.09	)		-
Outstanding as of September 30, 2015		12,867,334		$	1.30			3.96

	Number of			Weighted Average			Remaining Term
	Warrants			Exercise Price			(years)
Outstanding as of December 31, 2014		12,550,062			1.25			4.60
Granted		2,933,822			1.33			6.81
Cancelled/Expired		(2,697,508	)		(1.25	)		-
Outstanding as of June 30, 2015		12,786,376		$	1.28			4.30

On January 30, 2015 the Company issued 23,750 Class D warrants. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $1.25 stock price, $3.00 exercise price, 7 years to maturity, 137% volatility, and 1.49% risk free rate.

~~During~~On ~~the~~February ~~three months ending March 31~~27, 2015, the Company issued ~~118~~75,~~157~~657 ~~warrants~~Class asD ~~stock offering costs to a related party~~warrants. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $1.25 stock price, $23.00 exercise price, 7 years to maturity, ~~135.37~~136% volatility, and 1.7182% risk free rate.

On ~~February~~March 2731, 2015 the Company issued 7518,~~657~~750 Class D warrants. The warrants were not deemed to be derivative instruments because ~~they~~ they do not have a reset feature, and therefore no liability was booked related to the warrants. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $1.25 stock price, $3.00 exercise price, 7 years to maturity, ~~136~~135% volatility, and 1.8271% risk free rate.

On ~~March~~July 3129, 2015 the Company issued 1840,~~750~~480 Class D warrants. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $1.25 stock price, $3.00 exercise price, 7 years to maturity, ~~135~~168.60% volatility, and 12.7102% risk free rate.

On January 14, 2015, the Company voided and replaced 2,621,851.22 placement agent warrants that were issued to a related party. Of those warrants, 40,000 had an exercise price of $2.00 and 2,581,851 had an exercise price of $1.25, which will expire on the seventh anniversary of the effective date of a registration statement concerning the underlying common stock. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $1.25 stock price, $1.25 and $2.00 exercise price, 7 years to maturity, 144.70% volatility, 1.62% risk free rate. As a result of the modification, the Company recognized a loss on warrant modification of $29,610.

~~Options~~For the nine months ended September 30, 2015 the Company has issued a total of 158,635 Placement Agent warrants, of those 118,157 were related to stock offering costs issued to a related party. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $1.25 stock price, exercise price from $2-$3, 7 years to maturity, 168.60% volatility, and 2.02% risk free rate.

~~The Company has recorded stock compensation expense of $39,647 and $0 for the six months ended June 30, 2015 and 2014, respectively.~~Options

OnThe ~~March 20, 2015 the~~ Company ~~issued~~has ~~30,000~~recorded stock ~~options~~compensation toexpense ~~Arthur~~of ~~Bollon for services to be rendered during 2015. On the date granted~~$119,842 ~~one-quarter of the issued options vested~~ and ~~became~~$0 ~~exercisable. The remainder will vest quarterly~~ for the ~~next~~nine ~~three quarters.~~months ~~The~~ended ~~Company~~September ~~valued these warrants using the Black-Scholes independent direction options pricing model under the following assumptions: $1.25 stock price~~30, ~~$2.00~~2015 ~~exercise~~and ~~price~~2014, ~~5 years to maturity, 188% volatility, and 1~~respectively.~~37% risk free rate.~~

On March 20, 2015 the Company issued 30,000 stock options to ~~Jack~~Arthur ~~Levine~~Bollon for services to be rendered during 2015. On the date granted, one-quarter of the issued options vested and became exercisable. The remainder will vest quarterly for the next three quarters. The Company valued these warrants using the Black-Scholes independent ~~direction~~director ~~option~~options pricing model under the following assumptions: $1.25 stock price, $2.00 exercise price, 5 years to maturity, 188% volatility, and 1.37% risk free rate.

On ~~May~~March 120, 2015 the Company issued ~~300~~30,000 stock options to ~~Kai~~Jack ~~Larson,~~Levine ~~Vice~~for ~~President~~services ofto ~~Corporate~~be ~~Development~~rendered ~~and~~during ~~Chief~~2015. ~~Operating Officer,~~On asthe ~~part~~date granted, one-quarter of the ~~Company’s~~issued ~~incentive~~options ~~stock~~vested ~~option~~and ~~plan~~became exercisable. ~~These~~The ~~options~~remainder will vest inquarterly ~~equal monthly installments~~ for 72the ~~months,~~next orthree ~~six years, and will be fully vested April 2021~~quarters. The Company valued these options using the Black-Scholes independent ~~direction~~director option pricing model under the following assumptions: $1.25 stock price, $2.00 exercise price, 10 5 years to maturity, ~~105~~188% volatility, and 1.5037% risk free rate.

On May 1, 2015 the Company issued ~~450~~300,000 stock options to Kai Larson, ~~for~~Vice ~~services~~President toof beCorporate ~~rendered~~Development ~~during~~and ~~2015~~Chief Operating Officer, as part of the Company’s incentive stock option plan. These options will vest in equal monthly installments for 72 months, or six years, and will be fully vested April 2021. The Company valued these ~~warrants~~ options using the Black-Scholes independent director ~~direction~~ option pricing model under the following assumptions: $1.25 stock price, $2.00 exercise price, 10 years to maturity, 105% volatility, and 1.50% risk free rate.

9On May 1, 2015 the Company issued 450,000 stock options to Kai Larson for services to be rendered during 2015. These options will vest in equal monthly installments for 72 months, or six years, and will be fully vested April 2021.The Company valued these warrants using the Black-Scholes independent director option pricing model under the following assumptions: $1.25 stock price, $2.00 exercise price, 10 years to maturity, 105% volatility, and 1.50% risk free rate.

~~NOTE~~On 8September –4, ~~COMMITMENT~~2015, ~~AND~~the ~~CONTINGENCIES~~Company issued 25,000 stock options to James McChesney, a member of the Company’s Scientific Advisory Board, as part of the Company’s incentive stock option plan. These options will vest in two equal installments, the first 12,500 options vesting on August 10, 2016, and the second 12,500 options vesting on August 10, 2017. The Company valued these options using the Black-Scholes independent director option pricing model under the following assumptions: $1.25 stock price, $2.00 exercise price, 5 years to maturity, 162% volatility, and 1.47% risk free rate.

SignPath is obligated to pay running royalties of 2.5% on net sales of less than $250 million for products covered by an issued patent licensed under the UTMDACC License Agreement. This royalty rate increases to 3% for sales equal to, or greater than, $250 million. A royalty of 1.5% of net sales is payable by SignPath for products covered under the license which are not protected by an issued patent. After sales to the public begin, SignPath must pay a minimum annual royalty $75,000 which can be deducted from the royalties on net sales due under the agreement. In addition, SignPath is obligated to pay 20% to 25% of all non-royalty consideration received under sublicensing agreements.10

~~SignPath~~On ~~previously~~September ~~had~~4, 2015, the Company issued 25,000 stock options to Peter Sordillo, a ~~License~~member ~~Agreement~~of ~~with~~the ~~John~~Company’s ~~Hopkins~~Scientific ~~University~~Advisory Board, ~~that~~as part of the Company’s ~~terminated~~incentive instock ~~December~~option ~~2014~~plan. AsThese ~~part~~options are fully vested as of the ~~termination~~ date of grant, ~~the~~reflecting past services rendered. The Company ~~agreed~~valued tothese ~~pay~~options ~~JHU~~using the Black-Scholes independent director option pricing model under the following assumptions: $201.25 stock price,~~000~~ $2.00 exercise price, ~~due~~5 inyears ~~September~~to ~~2015~~maturity, 162% volatility, and 1.47% risk free rate.

OnNOTE ~~December~~8 ~~12,~~– ~~2014,~~COMMITMENT ~~the~~AND Board of Directors authorized an amendment to Dr. Helson’s employment agreement to provide that: (A) upon successful completion of Phase I trials for anti-Ebola testing in Africa paid for by the United States Army Medical Research Institute of Infectious Diseases (“USAMRIID”), exclusive of the cost of drug products and shipping, Dr. Helson would receive options to purchase 300,000 shares of Common Stock exercisable at then current fair market value and a cash bonus of $75,000, and (B) upon successful completion of Phase I trials in Vienna, Austria for the lead anti-QT prolongation drugs (Moxifloxacin) for liposomes Dr. Helson would receive additional options to purchase 300,000 shares of Common Stock exercisable at then current fair market value and a cash bonus of $75,000.CONTINGENCIES

OnSignPath ~~March~~is ~~27,~~obligated ~~2015,~~to ~~the~~pay ~~Board~~running royalties of ~~Directors~~2.5% ~~authorized~~on anet ~~bonus~~sales toof ~~Dr.~~less ~~Helson~~than ~~providing~~$250 ~~that:~~million ~~upon~~for ~~the~~products ~~closing~~covered ofby ~~financing~~an ~~for~~issued patent ~~$20~~licensed ~~million~~under orthe ~~more~~UTMDACC ~~with~~License ~~The~~Agreement. ~~Westbury~~This ~~Group~~royalty rate increases to 3% for sales equal to, or ~~any~~greater ~~other financing~~than, Dr$250 million. A ~~Helson~~royalty ~~would~~of be1.5% ~~awarded~~of anet ~~discretionary~~sales ~~bonus~~is ofpayable upby SignPath for products covered under the license which are not protected by an issued patent. After sales to ~~100%~~the ofpublic ~~his~~begin, ~~then~~SignPath ~~current~~must ~~salary~~pay ~~estimated~~a tominimum beannual royalty $~~375~~75,000 ~~per~~which ~~annum~~can be deducted from the royalties on net sales due under the agreement. In addition, SignPath is obligated to pay 20% to 25% of all non-royalty consideration received under sublicensing agreements.

OnSignPath ~~May~~previously 1,had ~~2015~~a ~~The~~License ~~Company~~Agreement ~~entered into an employment agreement~~ with ~~Mr.~~John ~~Kai~~Hopkins ~~Larson~~University ~~and~~that ~~appointed~~the ~~him~~Company asterminated ~~Vice~~in ~~President of~~December ~~Corporate Development, Chief Operating Officer, and Secretary~~2014. ~~Mr.~~As ~~Larson~~part ~~will have a salary~~ of ~~$200,000 per~~the ~~year~~termination, ~~$150,000 of which is deferred until such time that~~ the Company ~~raises~~paid anJHU ~~aggregate of~~ $~~10 million through either debt or equity financing~~20, ~~or licensing revenues. In addition, the Company granted Mr. Larson options to purchase 750,~~000 ~~shares of common stock as noted in Note 7~~.

~~NOTE~~On 9December 12, 2014, the Board of Directors authorized an amendment to Dr. Helson’s employment agreement to provide that: (A) upon successful completion of Phase I trials for anti-Ebola ~~SUBSEQUENT~~testing ~~EVENTS~~in Africa paid for by the United States Army Medical Research Institute of Infectious Diseases (“USAMRIID”), exclusive of the cost of drug products and shipping, Dr. Helson would receive options to purchase 300,000 shares of Common Stock exercisable at then current fair market value and a cash bonus of $75,000, and (B) upon successful completion of Phase I trials in Vienna, Austria for the lead anti-QT prolongation drugs (Moxifloxacin) for liposomes Dr. Helson would receive additional options to purchase 300,000 shares of Common Stock exercisable at then current fair market value and a cash bonus of $75,000.

On ~~July~~March 2927, 2015, the ~~Company~~Board ~~issued~~of ~~40,480~~Directors ~~Class~~authorized Da ~~warrants~~bonus ~~exercisable~~to ~~at $3~~Dr.00 ~~per~~Helson ~~share~~providing ~~with~~that: 7upon ~~years to maturity from~~ the ~~effective~~closing ~~date~~ of afinancing ~~registration~~for ~~statement.~~$20 million ~~The~~or ~~Company~~more ~~also~~with ~~issued~~The ~~324~~Westbury ~~shares~~Group, ofor ~~Series~~any Dother ~~Preferred~~financing, ~~Stock convertible at $2~~Dr.00 ~~per~~Helson ~~share~~would ~~into~~be anawarded ~~aggregate~~a ofdiscretionary ~~161,913~~bonus ~~shares~~ of ~~common~~up ~~stock.~~to ~~Gross proceeds received for these shares was $323,826~~100% ~~offset by stock offering costs~~ of ~~$50,883~~his ~~issued~~then tocurrent ~~the~~salary ~~placement~~estimated ~~agent, a related party. The Company also issued 40,478 placement agent warrants~~ to ~~the~~be ~~same related party with a~~ $~~2.00~~375,000 per ~~share exercise price, and 7 years to maturity from the effective date of a registration statement~~annum.

On May 1, 2015 The Company entered into an employment agreement with Mr. Kai Larson and appointed him as Vice President of Corporate Development, Chief Operating Officer, and Secretary. Mr. Larson will have a salary of $200,000 per year, $150,000 of which is deferred until such time that the Company raises an aggregate of $10 million through either debt or equity financing, or licensing revenues. In addition, the Company granted Mr. Larson options to purchase 750,000 shares of common stock as noted in Note 7.

~~ITEM~~NOTE 2.9 ~~Management’s~~– ~~Discussion~~SUBSEQUENT ~~and Analysis of Financial Condition and Results of Operations.~~EVENTS

~~The~~In ~~following~~accordance ~~discussion should be read in conjunction~~ with ~~the~~ASC ~~financial statements and notes thereto included in this report. Except for the historical information contained herein, the discussion in this report contains certain forward~~855-~~looking~~10 ~~statements that involve risk and uncertainties, such as statements of the~~ Company’s ~~plans,~~management ~~objectives,~~reviewed ~~expectations~~all ~~and~~material ~~intentions~~events asthrough of the date of this ~~filing.~~report ~~The~~and ~~cautionary~~had ~~statements~~no ~~made in this document should be read as being applicable to all related forward-looking~~material ~~statements~~subsequent ~~wherever they appear in this document~~events. The Company’s actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2014 as well as discussed elsewhere herein.

~~Liquidity and Capital Resources~~11

AsITEM of2. ~~June~~Management’s ~~30,~~Discussion ~~2015~~ and ~~December~~Analysis ~~31,~~of ~~2014,~~Financial ~~the~~Condition ~~Company had $665,781~~ and ~~$716,193,~~Results ~~respectively,~~ of ~~cash on hand~~Operations. ~~The Company had positive working capital of $337,993 at June 30, 2015 compared to $268,194 as of December 31, 2014. SignPath had an accumulated deficit of $14,302,744 as of June 30, 2015.~~

~~During~~The ~~the~~following ~~six~~discussion ~~months~~should ~~ended~~be ~~June~~read ~~30,~~in ~~2015,~~conjunction ~~SignPath~~with ~~sold~~the ~~945~~financial ~~Units~~statements ~~consisting~~and ofnotes ~~its~~thereto ~~securities~~included atin athis ~~price of $1,000 per Unit~~report. ~~The Units~~Except ~~sold~~for inthe ~~2015~~historical ~~consisted~~information ofcontained ~~Series~~herein, Dthe ~~Convertible~~discussion ~~Preferred~~in ~~Stock~~this ~~Units.~~report ~~Each~~contains ~~Unit~~certain ~~consists~~forward-looking ofstatements ~~(i) one share of 6.5% Series D Convertible~~that ~~Preferred~~involve ~~Stock~~risk ~~convertible~~and ~~into~~uncertainties, ~~500~~such ~~shares~~as statements of ~~common~~the ~~stock~~Company’s ~~(equivalent~~plans, toobjectives, ~~$2.00~~expectations ~~per~~and ~~share~~intentions ofas ~~common stock) following~~ of the ~~effective~~ date of ~~its~~this ~~Registration~~filing. ~~Statement~~The ~~(the~~cautionary ~~“Effective~~statements ~~Date”)~~made ~~subject~~in tothis ~~adjustment,~~document ~~and~~should ~~(ii)~~be ~~Warrants~~read toas ~~purchase~~being ~~125 shares~~applicable ofto ~~common~~all ~~stock~~related atforward-looking statements ~~$3.00~~wherever ~~per~~they ~~share~~appear ~~for~~in athis ~~seven-year~~document. ~~period~~The ~~following~~Company’s ~~the~~actual ~~Effective~~results ~~Date~~could ofdiffer amaterially ~~registration~~from ~~statement~~those ~~including~~discussed ~~the underlying securities~~here. ~~The~~Factors ~~Company~~that ~~received~~could ~~gross~~cause ~~proceeds~~differences ofinclude ~~$945,249~~those ~~and~~discussed ~~incurred~~in ~~stock~~the ~~offering~~“Risk ~~costs~~Factors” section of ~~$144,454~~our ~~related~~Annual Report toon ~~such~~Form ~~offerings~~10-K ~~paid~~for tothe ayear ~~related~~ended ~~party~~December 31, ~~during~~2014 ~~the~~as ~~six~~well ~~months~~as ~~ended~~discussed ~~June~~elsewhere ~~30, 2015~~herein.

~~Subsequent~~Liquidity to the end of the period, on July 29, 2015 the Company issued 324 Units consisting of its securities at a price of $1,000 per Unit. These Units consisted of Series D Preferred Stock Units. Each Unit consists of (i) one share of 6.5% Series D Convertible Preferred Stock convertible into 500 shares of common stock (equivalent to $2.00 per share of common stock) subject to adjustment, and ~~(ii)~~Capital Warrants to purchase 125 shares of common stock at $3.00 per share for a seven-year period following the Effective Date of a registration statement including the underlying securities. Gross proceeds received for these shares was $323,826 offset by stock offering costs of $50,883 issued to the placement agent, a related party.Resources

~~The~~As ~~Company~~of ~~has~~September ~~no agreements~~30, ~~arrangements~~2015 orand ~~understandings~~December ~~with any officer~~31, ~~director or shareholder as to any future financing~~2014, ~~either~~ ~~equity or debt. The Company expects to continue to incur losses for~~ the ~~foreseeable future and it is possible the~~ Company ~~may~~ ~~never~~had ~~reach profitability. Therefore~~$498,101 ~~the Company will require additional capital resources~~ and ~~financing~~$716,193, torespectively, ~~implement~~of ~~its business~~cash ~~plan~~on ~~and continue its operations~~hand. The Company~~’s current burn rate for salaries, research programs, patent filings,~~ ~~clinical~~had ~~trials,~~positive ~~and~~working ~~professional~~capital ~~fees~~of ~~averages about~~ $~~150~~201,~~000~~791 ~~per~~at ~~month.~~September ~~Thus~~30, it2015 iscompared ~~expected that the Company currently has sufficient cash on hand~~ to ~~operate~~$268,194 ~~through~~as ~~the next 4 months. In view~~ of ~~general~~December ~~economic conditions~~31, ~~there~~2014. ~~can~~SignPath behad noan ~~assurance~~accumulated ~~that~~deficit ~~any~~of ~~additional~~$14,779,840 ~~financing~~as ~~will~~of beSeptember ~~available to us~~30, ~~that any affiliate will provide additional investments in the Company or that adequate funds for our operations will otherwise be available when needed or on terms acceptable to us~~2015.

~~Cash~~During ~~used~~the innine ~~operating~~months ~~activities~~ended ~~decreased~~September by30, ~~$122~~2015,~~153~~ ~~from~~SignPath (sold 1,269 units consisting of its securities at a price of $~~973~~1,~~360~~000 per Unit. The Units sold in 2015 consisted of Series D Convertible Preferred Stock Units. Each Unit consists of (i) ~~for~~one ~~the~~share ~~six~~of ~~months~~6.5% ~~ended~~Series D ~~June~~Convertible ~~30,~~Preferred ~~2014~~Stock toconvertible into 500 shares of common stock (equivalent to $~~851,207~~2.00 per share of common stock) ~~for~~following the effective date of its Registration Statement (the ~~six~~ ~~months~~“Effective ~~ended~~Date”) ~~June~~subject 30to adjustment, ~~2015.~~and ~~The~~(ii) Warrants to purchase 125 shares of common stock at $~~122,153~~3.00 ~~decrease~~per isshare ~~due~~for toat aanytime ~~decrease~~after inissuance ~~net~~and ~~loss~~prior to the seventh anniversary of ~~$270,743~~the Effective ~~offset~~Date byof a ~~decrease~~registration instatement ~~noncash~~including the underlying securities. The Company received gross proceeds of $1,269,076 ~~expenses~~and incurred stock offering costs of $~~103~~195,~~237~~337 ~~and~~related ~~due~~to such offerings paid to ana ~~increase~~related inparty, during the ~~accounts~~nine ~~payable~~months ~~balance~~ended September ~~of $45~~30,~~353~~ 2015.

11The Company has no agreements, arrangements or understandings with any officer, director or shareholder as to any future financing, either equity or debt. The Company expects to continue to incur losses for the foreseeable future and it is possible the Company may never reach profitability. Therefore, the Company will require additional capital resources and financing to implement its business plan and continue its operations. The Company’s current burn rate for salaries, research programs, patent filings, clinical trials, and professional fees averages about $160,000 per month. Thus, it is expected that the Company currently has sufficient cash on hand to operate through the next 3 months. In view of general economic conditions, there can be no assurance that any additional financing will be available to us, that any affiliate will provide additional investments in the Company or that adequate funds for our operations will otherwise be available when needed or on terms acceptable to us.

~~The~~Cash ~~Company~~used ~~had~~in ~~net~~operating ~~cash~~activities ~~provided~~decreased by ~~financing~~$144,333 ~~activities~~from of ($~~800~~1,~~795~~436,164) ~~during~~for the ~~six~~nine months ended ~~June~~September 30, 2014 to ($1,291,831) for the nine months ended September 30, 2015. The $144,333 asdecrease is due to a ~~result~~decrease ofin ~~the~~common stock issued for services of $~~945~~51,~~249~~000, ~~received~~a decrease in astock ~~Private~~options ~~Placement,~~for ~~reduced~~compensation byof $~~144~~42,~~454~~896, a decrease of ~~offering~~$7,152 ~~costs.~~in ~~During~~prepaid ~~the~~expenses, ~~six~~and ~~months~~a ~~ended~~decrease ~~the~~in ~~Company~~accounts ~~had~~payable of $1563,~~372,536~~534. ofThis ~~net~~was ~~cash~~offset ~~provided~~ by ~~financing~~a ~~activities~~decrease asin anet ~~result~~loss of ~~the~~ $1776,~~620~~436,~~000~~ ~~received~~increase ~~from~~in astock ~~Private~~issued ~~Placement~~for compensation of ~~Preferred~~$16,000, ~~Stock~~and ~~less~~increase ~~the~~in ~~stock~~loss ~~offering~~on ~~costs~~equity modification of $~~247~~16,~~464~~478.

AsThe aCompany ~~result~~had ofnet ~~the~~cash ~~foregoing,~~provided ~~the~~by ~~Company’s~~financing ~~cash~~activities ~~decreased~~of by $501,~~412~~073,739 during the ~~six~~nine months ended ~~June~~September 30, 2015, as a result of the $1,269,076 received in a Private Placement, reduced by $195,337 of offering costs.

~~The~~As ~~financial statements included in this report have been prepared in conformity with generally accepted accounting principles that contemplate our continuance as~~ a ~~going~~result ~~concern.~~of ~~The Company has had no revenues and has generated losses from operation. As set forth in Note 2 to~~ the ~~audited Financial Statements~~foregoing, the ~~continuation of the~~ Company’s ascash adecreased ~~going~~by ~~concern~~$218,092 isduring ~~dependent upon~~ the ~~Company~~ ~~obtaining~~nine ~~adequate~~months ~~capital~~ended toSeptember ~~fund operating losses until it becomes profitable~~30, ~~if ever~~2015. The financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

~~Results~~The financial statements included in this report have been prepared in conformity with generally accepted accounting principles that contemplate our continuance as a going concern. The Company has had no revenues and has generated losses from operation. As set forth in Note 2 to the audited Financial Statements, the continuation of ~~Operations~~the Company as a going concern is dependent upon the Company obtaining adequate capital to fund operating losses until it becomes profitable, if ever. The financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

~~Material Changes in Results of Operations~~12

~~For~~Results ~~the~~of ~~six months ended June 30, 2015, as compared with the six months ended June 30, 2014~~ Operations

~~Total~~Material ~~operating~~Changes ~~expenses decreased by $1,067,343 to $899,842 for the six months ended June 30, 2015 from $1,157,285 for the six months ended, primarily as a result of research and development decreasing to $409,645~~ in ~~the~~Results ~~2015 period from $746,538 in the 2014 period. Lower R&D expenses are in part a result~~ of the Company focusing its R&D expenditures on cancer and cardiac arrhythmia, and curtailing expenditures in all other areas of research and development. General and administrative increased to $120,267 in the 2015 period from $14,460 in the 2014 period. This was due to an increase in travel expense of $10,165, recognizing $29,610 loss on equity modification for the six months ended June 30, 2015 with no such activity in the 2014 period, and $65,828 in payroll taxes that were re-classed to general and administrative for the six months ended June 30, 2015. Professional fees decreased by $11,309 from $231,970 in the 2014 period to $220,661 in the 2015 period. This resulted from a decrease in stock for compensation of $132,351 offset by increases in legal fees of $65,908, accounting fees of $19,107, Audit fees of $14,250, and general consulting fees of $17,641.Operations

~~Research~~For ~~and Development fees for~~ the ~~six~~nine months ended ~~June~~September 30, 2015, included payments to Cesar, ClinicPace Worldwide, & IPS Therapeutique for, $65,498, $79,493, and $68,491, respectively, for lab fees and other costs related to the Company’s research and development efforts. The Company incurred $115,109, in legal fees classified as research and development related to legal counsel’s work on patents, related filing documents, reviewing contracts, and filing disclosure statements. The decrease in research and development expenses to $409,194 for the six months ended June 30, 2015 from $746,538 for the six months ended June 30, 2014 is a result of drug development decreasing to $104,346 for the 2015 period as compared towith ~~$114,090 for~~ the ~~2014~~nine period, a decrease of $9,744 or 8.54%. In addition to the decrease in drug development costs, costs relating to patents licensed from Johns Hopkins (which license was terminated by the Company December 2014) decreased to $0 for the 2015 period from $116,135 for the 2014 period, legal fees related to research and development were $115,109 compared to $39,263, an increase of $75,846 or 193.18% for the six months ended ~~June~~September 30, ~~2015 and from the comparable period ended June 30,~~ 2014.

AsTotal operating expenses decreased by $760,726 to $1,375,518 for the nine months ended September 30, 2015 from $2,136,244 for the nine months ended September 30, 2014, primarily as a result of ~~the~~research ~~foregoing~~and development decreasing to $683,802 for the ~~Company~~nine ~~had~~months ended aSeptember ~~net~~30, ~~loss~~2015 offrom $~~886~~1,~~146~~546,500 for the ~~six~~nine months ended ~~June~~September 30, ~~2015~~2014. asLower ~~compared~~R&D expenses are in part a result of the Company focusing its R&D expenditures on cancer and cardiac arrhythmia, and curtailing expenditures in all other areas of research and development. General and administrative increased to $157,181 in the 2015 period from $60,041 in the 2014 period. aThis ~~net~~was ~~loss~~due to an increase in travel expense of $14,~~156~~275,~~889~~ an increase of $14,285 for loss on equity, and $81,353 in payroll taxes that were re-classed to general and administrative for the ~~six~~nine months ended ~~June~~ September 30, 2015 compared to $10,059 for the nine months ended September 30, 2014. Professional fees decreased by $53,704 from $320,176 in the 2014 period to $266,472 in the 2015 period. This resulted from an increase of $19,774 in accounting fees, $10,900 in audit fees, $25,524 in consulting fees, $29,120 in legal fees, and $22,568 in stock compensation, offset by a $161,590 decrease in stock issued for professional services rendered to the Company.

~~For~~Research and Development fees for the ~~three~~nine months ended ~~June~~September 30, 2015, included payments to Cesar, ClinicPace Worldwide, IPS Therapeutique, Nucro Technology, & Polymun for, $90,284, $48,650, and $80,401, $105,653, and $78,813, respectively, for lab fees and other costs related to the Company’s research and development efforts. The Company incurred $141,371, in legal fees classified as ~~compared~~research ~~with~~and development related to legal counsel’s work on patents, related filing documents, reviewing contracts, and filing disclosure statements. The decrease in research and development expenses to $683,802 for the ~~three~~nine months ended ~~June~~September 30, 2015 from $1,546,500 for the nine months ended September 30, 2014 is a result of drug development decreasing to $540,616 for the 2015 period as compared to $1,346,535 for the 2014 period, a decrease of $805,919. The decrease is a result of the Company focusing on cancer and cardiac arrhythmia clinical trials, and curtailing expenditures in all other areas. In addition to the decrease in drug development costs, costs relating to patents licensed from Johns Hopkins (which license was terminated by the Company December 2014) decreased to $0 for the 2015 period from $116,966 for the 2014 period, legal fees related to research and development were $141,371 for the 2015 period compared to $80,235, an increase of $61,136.

~~Total~~As ~~operating expenses for the three months ended June 30, 2015 decreased to $447,746 as compared with $958,913 for the three months ended June 30, 2014, primarily as~~ a result of ~~research and development expenses decreased to $193,141 in~~ the ~~2015 period from $616~~foregoing,~~750~~ in the ~~2014~~Company ~~period.~~had ~~Lower R&D expenses are, in part,~~ a ~~result~~net ofloss ~~the Company focusing its R&D expenditures on cancer and cardiac arrhythmia, and curtailing expenditures in all other areas~~ of ~~research and development. General and administrative increased to~~ $691,~~728 in the 2015 period from $6~~363,~~700~~242 ~~in the 2014 period due to travel expense increasing $12,512 from $265~~ for the ~~three~~nine months ended ~~June~~September 30, ~~2014 to $12,777 for the three months ended June 30,~~ 2015, ~~and~~as ~~$45,022~~compared ~~in payroll taxes that were re-classed~~ to ~~general and administrative for the three months ended June 30, 2015. Professional fees~~ ~~decreased~~a tonet ~~$103,495~~loss ~~in the 2015 period from $227,719 in the 2014 period due in part to stock for compensation expense~~ of $~~167~~2,~~113 for the three months ended June 30~~139,679 ~~2014, decreased $132,478 to $34,635~~ for the ~~three~~nine months ~~ended~~ June 30, 2015. Salaries and wages decreased to $81,382 in the 2015 period from $107,745 in the 2014 period due to $34,000 in common stock issued for services rendered to the Company in the three months ended ~~June~~September 30, 2014 ~~with no such activity in the 2015 period~~.

12For the three months ended September 30, 2015, as compared with the three months ended September 30, 2014

~~Research~~Total ~~and~~operating ~~Development~~expenses ~~fees~~ for the three months ended ~~June~~September 30, 2015, ~~included~~decreased ~~payments~~ to ~~Cesar~~$475,676 ~~ClinicPace~~as ~~Worldwide~~compared with $978,958 &for ~~IPS~~the three ~~Therapeutique~~months ~~for,~~ended $0September 30, ~~$21~~2014,~~216,~~ ~~and~~primarily ~~$50,831,~~as ~~respectively,~~a ~~for~~result ~~lab~~of ~~fees~~research and ~~other~~development ~~costs~~expenses ~~related~~decreased to $274,157 in the ~~Company’s~~2015 ~~research~~period ~~and~~from ~~development~~$799,965 ~~efforts~~in the 2014 period. ~~The~~Lower ~~Company~~R&D ~~incurred~~expenses ~~$71~~are,~~462~~ in part, a result of the Company focusing its R&D expenditures on cancer and cardiac arrhythmia, and curtailing expenditures in ~~legal~~all ~~fees~~other ~~classified~~areas asof research and development. ~~related~~General and administrative decreased to ~~legal~~$36,914 ~~counsel’s~~in ~~work~~the on2015 ~~patents,~~period ~~related~~from ~~filing documents~~$45,852 ~~reviewing~~in ~~contracts,~~the ~~and~~2014 ~~filing~~period ~~disclosure statements.~~due ~~The~~to a decrease in ~~research~~filing fees of $11,172, and ~~development~~decrease in istravel aof ~~result~~$5,891 of ~~drug~~set ~~development~~by ~~costs~~an increase of $215,~~340~~465 ~~for~~in ~~the~~payroll ~~three months~~taxes ~~ended~~that ~~June~~were ~~30,~~re-classed ~~2015~~to asgeneral ~~compared~~and toadministrative ~~$79,834~~ for the three months ended September 30, a2015, ~~decrease~~and an increase of $592,~~028~~344 orin 73insurance expense.~~94%.~~ InProfessional ~~addition~~fees decreased to $45,811 in the ~~decrease~~2015 period from $88,204 in ~~drug~~the ~~development~~2014 ~~costs,~~period ~~legal~~due ~~fees~~in ~~related~~part to ~~research~~stock ~~and~~for ~~development~~compensation ~~were~~expense of $7110,~~462~~806 ~~compared~~for tothe ~~$32,666,~~three anmonths ~~increase~~ended ofSeptember ~~$38~~30,~~796~~ or2014 ~~118.77%~~with no such activity for the three months ended ~~June~~September 30, 2015 ~~from the comparable period ended~~.

AsSalaries aand ~~result~~wages ofincreased ~~the~~to ~~foregoing~~$118,794 in the ~~Company~~2015 ~~had~~period afrom ~~net~~$45,207 ~~loss~~in the 2014 period, an increase of $~~440~~73,~~682~~587 due to $67,950 in common stock issued for services rendered to the Company in the three months ended ~~June~~September 30, 2015 aswith ~~compared to~~no asuch ~~net~~activity ~~loss~~in ~~of $958,713 for~~ the ~~three months ended~~2014 period.

~~Plan of Operations~~13

~~Manufacturing~~Research ofand ~~GMP~~Development ~~grade~~fees ~~synthesized~~for ~~curcumin~~the isthree ~~continuing~~months atended ~~Sami~~September ~~labs~~30, in2015, ~~India.~~included ~~Over~~payments ~~4.3~~to ~~kilograms~~Cesar, ofClinicPace ~~the~~Worldwide, ~~active~~IPS ~~principle~~Therapeutique, Nucro ~~was~~Technology, ~~sent~~& ~~to Dalton~~Polymun ~~Pharma~~for, ~~Services~~$30,510, in$3,552, ~~Canada~~$3,200, $71,968, & $20,707, respectively, for ~~analytical~~lab fees and ~~continuing~~other ~~stability~~costs related ~~testing~~to the Company’s research and development efforts. ~~Aliquots~~The ofCompany ~~curcumin~~incurred ~~are~~$26,261, ~~sent~~in tolegal ~~Polymun~~fees ~~Scientific~~classified as research inand ~~Austria~~development related to ~~manufacture~~legal ~~the~~counsel’s ~~formulated~~work ~~GMP~~on ~~grade~~patents, ~~liposomal~~related ~~curcumin~~filing ~~product~~documents, reviewing contracts, and filing disclosure statements. The ~~product~~decrease in research and development is ~~further~~a ~~analyzed~~result of drug development costs of $246,080 for ~~endotoxins~~the three months ended inSeptember ~~Gibraltar~~30, ~~Labs~~2015 inas ~~New~~compared ~~Jersey~~to $758,562 ~~and~~ for ~~release~~the ~~kinetics~~three atmonths ~~Northern~~ended ~~Lipids~~September in30, ~~Canada~~2014, a decrease of $512,482. The ~~final~~decrease is ~~product~~a ~~has~~result ~~been~~of ~~used~~the inCompany ~~45 human~~focusing ~~normal~~on ~~subjects~~cancer inand acardiac ~~Phase~~arrhythmia Iaclinical ~~ascending~~trials, ~~dose~~and ~~trial~~curtailing expenditures in ~~Austria~~all other areas. ~~Based~~In ~~upon~~addition ~~these~~to ~~data,~~the adecrease ~~Phase~~in Ibdrug ~~ascending~~development ~~dose~~costs, ~~clinical trial~~legal isfees ~~ongoing~~related into ~~Austria:~~research ~~accruing~~and asdevelopment ofwere ~~this~~$26,261 ~~date~~compared to 24$40,972, ~~cancer~~a ~~patients~~decrease ~~who~~of ~~progressed~~$14,711 onfrom ~~standard~~the ofcomparable ~~care~~period ~~therapy.~~ended ~~The~~September ~~purpose of~~30, ~~this~~2015 ~~study~~and is2014, torespectively, ~~ascertain~~resulting ~~side~~from ~~effects~~legal work ~~and~~previously ~~appropriate~~handled ~~dosing~~by ~~levels~~outside ofcounsel ~~liposomal~~being ~~curcumin~~handled internally by the Company.

~~Upon~~As ~~completion~~a result of the ~~Phase Ib ascending dose trial in Austria~~foregoing, the Company ~~plans~~had ~~to initiate Phase II trials for liposomal curcumin in glioblastoma (~~a ~~brain~~net ~~tumor)~~loss ~~and non-small cell lung cancer in patients who have progressed on standard~~ of ~~care~~$477,096, ~~therapy.~~for ~~Because of~~ the ~~high~~three ~~costs~~months ofSeptember ~~conducting~~30, ~~clinical~~2015 ~~trials~~as ~~in the United States~~ compared ~~with other jurisdictions, the Company plans~~ to ~~conduct~~a net ~~these~~loss ~~Phase~~of ~~II trials in primarily in Western Europe~~$982,790 ~~with~~for the ~~majority~~three ofmonths ~~the~~ended ~~trial~~September ~~centers~~30, ~~located in Austria and Germany~~2014.

~~The~~Plan ~~Company~~of has made a decision to focus its resources on cancer and cardiac arrhythmia research and development at this time, so the planned FDA submission on Parkinson’s disease and the associated expenditures supporting this effort have been suspended.Operations

~~The~~Manufacturing ~~liposome~~of ~~composed~~GMP ofgrade ~~DMPC~~synthesized ~~and~~curcumin ~~DMPG~~is ~~was~~continuing ~~initially~~at ~~discovered~~Sami tolabs, ~~prevent~~in ~~curcumin~~India. ~~induced~~Over ~~cardiac~~4.3 ~~arrhythmias~~kilograms inof inthe ~~vitro,~~active inprinciple exwas sent to ~~vivo~~Dalton ~~studies~~Pharma Services in ~~rabbit~~Canada ~~models,~~for analytical and incontinuing ~~vivo~~stability intesting. ~~rabbit~~Aliquots ~~models~~of ~~challenged~~curcumin ~~with~~are ~~clinically~~sent ~~approved~~to ~~QTc~~Polymun ~~prolonging anticancer drugs,~~Scientific ~~Crizotinib~~in ~~and~~Austria ~~Nilotinib.~~to ~~The~~manufacture ~~Company~~the isformulated ~~collaborating~~GMP ~~with~~grade ~~Avanti~~liposomal ~~Polar~~curcumin ~~Inc~~product. ~~and~~The ~~IPS~~product ~~Therapeutique,~~is ~~Canada~~further inanalyzed ~~further~~for ~~research~~endotoxins ~~and~~in ~~development~~Gibraltar ~~relating~~Labs toin ~~controlling~~New ~~cardiac~~Jersey, ~~arrhythmia~~and ~~side~~for ~~effects~~release ~~for~~kinetics aat ~~broad~~Northern ~~range~~Lipids ofin ~~drugs~~Canada. ToThe ~~date,~~final aproduct ~~lead~~has ~~compound~~been ~~has~~used in 45 ~~been~~human ~~identified,~~normal ~~and~~subjects ~~work~~in isa ~~under~~Phase ~~way~~Ia toascending ~~generate~~dose ~~the~~trial ~~pre~~in ~~clinical~~Austria. ~~data~~Based ~~necessary~~upon tothese ~~initiate~~data, ~~clinical~~a ~~trials~~Phase ~~with~~Ib ~~this~~ascending ~~compound.~~dose clinical ~~Negotiations~~trial ~~are~~is ~~also~~ongoing in ~~progress~~Austria: ~~between~~accruing ~~Avanti~~as ~~Polar,~~of ~~IPS,~~this ~~and~~date ~~the~~26 ~~Company~~cancer ~~regarding~~patients ~~ownership,~~who ~~licensing,~~progressed ~~and~~on ~~exploitation~~standard of care therapy. The purpose of ~~the~~this ~~intellectual~~study ~~property~~is ~~resulting~~to ~~from~~ascertain ~~these~~side ~~collaborative~~effects ~~efforts~~and appropriate dosing levels of liposomal curcumin.

~~Item~~Upon 3.completion ~~Quantitative~~of the Phase Ib ascending dose trial in Austria, the Company plans to initiate Phase II trials for liposomal curcumin in glioblastoma (a brain tumor) and ~~Qualitative~~non-small ~~Disclosures~~cell ~~About~~lung ~~Market~~cancer ~~Risk~~in patients who have progressed on standard of care therapy. Because of the high costs of conducting clinical trials in the United States compared with other jurisdictions, the Company plans to conduct these Phase II trials in primarily in Western Europe, with the majority of the trial centers located in Austria and Germany.

~~Not~~The ~~Required~~Company has made a decision to focus its resources on cancer and cardiac arrhythmia research and development at this time, so the planned FDA submission on Parkinson’s disease and the associated expenditures supporting this effort have been suspended.

13The liposome composed of DMPC and DMPG was initially discovered to prevent curcumin induced cardiac arrhythmias in in vitro, in ex vivo studies in rabbit models, and in vivo in rabbit models challenged with clinically approved QTc prolonging anticancer drugs, Crizotinib and Nilotinib. The Company is collaborating with Avanti Polar Inc. and IPS Therapeutique, Canada in further research and development relating to controlling cardiac arrhythmia side effects for a broad range of drugs. To date, a lead compound has been identified, and work is under way to generate the pre clinical data necessary to initiate clinical trials with this compound. Negotiations are also in progress between Avanti Polar, IPS, and the Company regarding ownership, licensing, and exploitation of the intellectual property resulting from these collaborative efforts.

Item 43. ~~Controls~~Quantitative and ~~Procedures.~~Qualitative Disclosures About Market Risk

~~Disclosure~~Not ~~Controls and Procedures~~Required

AsItem of June 30, 2015, the Company’s management evaluated, with participation of its principal executive officer and its principal financial officer, the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a15 of the Securities Exchange Act of 1934, as amended (the Exchange Act)4. ~~Based~~Controls ~~on that evaluation, the Company’s principal executive officer~~ and ~~its principal financial officer concluded that the Company’s disclosure controls and procedures were ineffective as of June 30, 2015~~Procedures.

~~Management~~Disclosure ~~assessed~~Controls the effectiveness of our internal control over financial reporting as of the Evaluation Date based on criteria for effective internal control over financial reporting described in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. The material weaknesses identified during management’s assessment were (i) a lack of sufficient internal accounting resources; and (ii) a lack of segregation of duties to ensure adequate review of financial statement preparation. In light of these material weaknesses, management has concluded that we did not maintain effective internal control over financial reporting at the Evaluation Date.Procedures

~~Change~~As of September 30, 2015, the Company’s management evaluated, with participation of its principal executive officer and its principal financial officer, the effectiveness of the Company’s disclosure controls and procedures, as defined in ~~Internal~~Rules 13a-15 ~~Control~~of ~~over~~the ~~Financial~~Securities ~~Reporting~~Exchange Act of 1934, as amended (the Exchange Act). Based on that evaluation, the Company’s principal executive officer and its principal financial officer concluded that the Company’s disclosure controls and procedures were ineffective as of September 30, 2015.

~~There~~Management ~~were~~assessed nothe ~~changes~~effectiveness inof our internal control over financial reporting as of the ~~Company’s~~Evaluation Date based on criteria for effective internal control over financial reporting ordescribed in ~~any~~Internal ~~other~~Control—Integrated ~~factors~~Framework ~~that~~issued ~~could~~in ~~significantly~~1992 by the Committee ~~affect~~of ~~these~~Sponsoring ~~controls,~~Organizations ~~during~~of the ~~Company~~Treadway Commission. The material weaknesses identified during management’s ~~quarter~~assessment were ~~ended~~(i) ~~June~~a ~~30,~~lack ~~2015,~~of ~~that~~sufficient ~~have~~internal ~~materially~~accounting ~~affected,~~resources; orand ~~are~~(ii) ~~reasonably likely~~a lack of segregation of duties to ~~materially~~ensure ~~affect~~adequate review of financial statement preparation. In light of these material weaknesses, ~~the~~management ~~Company’s~~has concluded that we did not maintain effective internal control over financial reporting at the Evaluation Date.

~~PART~~Change ~~II.~~in ~~OTHER~~Internal ~~INFORMATION~~Control over Financial Reporting

~~Item~~There 1.were ~~Legal~~no ~~Proceedings~~changes in the Company’s internal control over financial reporting or in any other factors that could significantly affect these controls, during the Company’s quarter ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

~~As of the date of this Quarterly Report on Form 10-Q, we are not a party to any legal proceedings.~~14

~~Item~~PART 1AII. OTHER ~~Risk Factors~~INFORMATION

InItem ~~accordance~~1. ~~with~~Legal ~~the requirements of Form 10-Q, the Company, as a smaller reporting company, is not required to make disclosure under this item~~Proceedings.

~~Item~~As 2.of ~~Unregistered~~the ~~Sales~~date of ~~Equity~~this ~~Securities~~Quarterly ~~and~~Report ~~Use~~on ofForm ~~Proceeds~~10-Q, we are not a party to any legal proceedings.

~~During~~Item ~~the six-month period ended June 30, 2015, this Registrant sold 945 units (the “Units”) of its securities at a price of $1,000 per unit or 945,249~~1A. ~~Each~~Risk Unit consists of (i) one share of 6.5% Series D Convertible Preferred Stock convertible into 500 shares of common stock (equivalent to $2.00 per share of common stock) subject to adjustment, and (ii) Warrants to purchase 125 shares of common stock at $3.00 per share ending seven years following the Effective Date of its registration statement. The Company received gross proceeds of $945,249 and paid 10% sales commissions of $144,454 to Meyers Associates, L.P., the Company’s placement agent and related party.Factors

~~The~~In ~~Units~~accordance ~~were~~with ~~sold to 19 accredited investors who were customers of~~ the ~~placement~~requirements ~~agent. The Company claimed an exemption from registration pursuant to Section 4(a)(2)~~ of ~~the~~Form ~~Securities Act of 1933~~10-Q, ~~as amended (~~the ~~“Securities Act”) and Rule 506 of Regulation D promulgated thereunder~~Company, ~~based~~as ~~upon~~ a ~~subscription~~smaller ~~agreement~~reporting ~~executed by such investor. The net proceeds of the offering were used for working capital~~company, ~~research~~is ~~and~~not ~~development~~required ~~and~~to ~~clinical~~make ~~trials in Europe towards filing an investigational new drug application~~disclosure tounder ~~commence~~this ~~clinical trials in the United States~~item.

~~During~~Item the six-month period ended June 30, 2015, the Registrant issued 40,000 shares of common stock to Jack Levine, an independent director, for services rendered as Chairman of the Company’s Audit Committee during 20142. ~~The~~Unregistered ~~Company~~Sales ~~claimed an exemption from registration pursuant to Section 4(a)(2)~~ of ~~the~~Equity Securities ~~Act. No commissions were paid~~ and noUse ~~placement~~of ~~agent or underwriter was involved in the transaction~~Proceeds.

~~Item~~During the nine-month period ended September 30, 2015, this Registrant sold 1,269 units (the “Units”) of its securities at a price of $1,000 per unit or 1,268,948. Each Unit consists of (i) one share of 6.5% Series D Convertible Preferred Stock convertible into 500 shares of common stock (equivalent to $2.00 per share of common stock) subject to adjustment, and (ii) Warrants to purchase 125 shares of common stock at $3.00 ~~Defaults~~per ~~Upon~~share ~~Senior~~ending ~~Securities~~seven years following the Effective Date of its registration statement. The Company received gross proceeds of $1,269,076 and paid sales commissions of $195,337 to Meyers Associates, L.P., the Company’s placement agent and related party.

~~None~~The Units were sold to 33 accredited investors who were customers of the placement agent. The Company claimed an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated thereunder, based upon a subscription agreement executed by such investor. The net proceeds of the offering were used for working capital, research and development and clinical trials in Europe towards filing an investigational new drug application to commence clinical trials in the United States.

~~Item~~During the nine-month period ended September 30, 2015, the Registrant issued 40,000 shares of common stock to Jack Levine, an independent director, for services rendered as Chairman of the Company’s Audit Committee during 2014. The Company claimed an exemption from registration pursuant to Section 4(a)(2) of the Securities Act. ~~Mine~~No ~~Safety~~commissions ~~Disclosures~~were paid and no placement agent or underwriter was involved in the transaction.

~~None~~Item 3. Defaults Upon Senior Securities.

~~Item 5~~None. ~~Other Information~~

~~None~~Item 4. Mine Safety Disclosures

14None.

Item 65. ~~Exhibits.~~Other Information

~~Exhibits~~None.

~~Set forth below is a list of the exhibits to this quarterly report on Form 10-Q.~~15

	Exhibit Number	Description
	3.1	Certificate of Incorporation of the registrant (1)
	3.2	Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock (1)
	3.3	Amended and Restated Certificate of Incorporation of the registrant dated August 2, 2006 (1)
	3.4	Certificate of Amendment of the Registrant dated May 27, 2008 (1)
	3.5	Certificate of Designation Preference and Rights of Series B Convertible Preferred Stock (3)
	3.6	Certificate of Amendment of the Registrant dated October 20, 2011 (2)
	3.7	Certificate of Designation, Preferences and Rights of Series C Convertible Preferred Stock (4)
	3.8	Certificate of Designation, Preferences and Rights of Series D Convertible Preferred Stock (5)
	3.9	By-Laws of the registrant (1)
	4.1	Form of Common Stock Certificate (1)
	4.2	Form of Class C Common Stock Purchase Warrant (4)
	4.3	Form of Bridge Note (1)
	4.4	Form of Series A Subscription Rights Agreement (1)
	4.5	Form of Series A Subscription Agreement (1)
	4.6	Form of Series B Subscription Agreement (3)
	4.7	Form of Series C Subscription Agreement (4)
	4.8	Form of Registration Rights Agreement (4)
	4.9	Form of Class D Common Stock Purchase Warrant(6)
	4.10	Form of Series D Subscription Agreement (6)
	*31.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	*32.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Item 6. Exhibits.

~~_______________~~Exhibits.

*Set ~~Filed~~forth ~~with~~below is a list of the exhibits to this ~~Report~~quarterly report on Form 10-Q.

(1) Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No. 333-158474, declared effective on August 10, 2009.

Exhibit Number		Description

3.1		Certificate of Incorporation of the registrant (1)

3.2		Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock (1)

3.3		Amended and Restated Certificate of Incorporation of the registrant dated August 2, 2006 (1)

3.4		Certificate of Amendment of the Registrant dated May 27, 2008 (1)

3.5		Certificate of Designation Preference and Rights of Series B Convertible Preferred Stock (3)

3.6		Certificate of Amendment of the Registrant dated October 20, 2011 (2)

3.7		Certificate of Designation, Preferences and Rights of Series C Convertible Preferred Stock (4)

3.8		Certificate of Designation, Preferences and Rights of Series D Convertible Preferred Stock (5)

3.9		By-Laws of the registrant (1)

4.1		Form of Common Stock Certificate (1)

4.2		Form of Class C Common Stock Purchase Warrant (4)

4.3		Form of Bridge Note (1)

4.4		Form of Series A Subscription Rights Agreement (1)

4.5		Form of Series A Subscription Agreement (1)

4.6		Form of Series B Subscription Agreement (3)

4.7		Form of Series C Subscription Agreement (4)

4.8		Form of Registration Rights Agreement (4)

4.9		Form of Class D Common Stock Purchase Warrant(6)

4.10		Form of Series D Subscription Agreement (6)

*31.1		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*32.1		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~(2)~~* Filed ~~Incorporated~~with bythis ~~reference to the Company’s Form 8-K for October 20, 2011 filed on October 21, 2011~~Report.

(3) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for September 30, 2011 filed on November 21, 2011.

(1)	Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No. 333-158474, declared effective on August 10, 2009.

(2)	Incorporated by reference to the Company’s Form 8-K for October 20, 2011 filed on October 21, 2011.

(3)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for September 30, 2011 filed on November 21, 2011.

(4)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for March 31, 2013 filed on May 15, 2013.

(5)	Incorporated by reference to the Company’s Registration Statement on Form S-1 (No. 333-198110) filed on December 12, 2014.

(6)	Incorporated by reference to the Company’s Annual Report on Form 10-K for December 31, 2014 filed on April 9, 2015.

~~(4) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for March 31, 2013 filed on May 15, 2013.~~16

~~(5) Incorporated by reference to the Company’s Registration Statement on Form S-1 (No. 333-198110) filed on December 12, 2014.~~SIGNATURES

~~(6)~~In accordance ~~Incorporated~~with bythe ~~reference~~requirements toof the ~~Company’s~~Exchange ~~Annual~~Act, ~~Report~~the onregistrant ~~Form~~caused ~~10-K~~this ~~for~~report ~~December~~to ~~31,~~be ~~2014~~signed ~~filed~~ on ~~April~~its 9behalf by the undersigned, thereunto ~~2015~~duly authorized.

Dated: November 16, 2015	SIGNPATH PHARMA INC.

	By:	*/s/ Lawrence Helson*
		Lawrence Helson, M.D., Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

~~SIGNATURES~~17

In SignPath ~~accordance~~Pharma ~~with~~Inc. Quarterly ~~the~~Report ~~requirements of the Exchange Act, the registrant caused this report to be signed~~ on ~~its~~Form ~~behalf~~10-Q Quarter byEnded ~~the~~September ~~undersigned~~30, ~~thereunto~~ ~~duly authorized.~~2015

Dated: August 14, 2015	SIGNPATH PHARMA INC.
	By:	/s/ Lawrence Helson
		Lawrence Helson, M.D., Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

EXHIBITS

Exhibit Number		Description

31.1		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~SignPath Pharma Inc.~~18

Quarterly Report on Form 10-Q

Quarter Ended June 30, 2015

EXHIBITS

Exhibit Number	Description
31.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Filing Compare · SignPath Pharma, Inc.